primary immune thrombocytopenia purpura. Other coagulation defects
Conditions
Interventions
Intervention 1: The first group: they will receive pulse methylprednisolone 2-3 mg/kg intravenously for 3 days every 2 weeks for 4 weeks until re-examination. Intervention 2: Control group: They will
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: age of 18-60 years, having a normal spleen size suffering from Immune thrombocytopenia (ITP)
Exclusion criteria
Exclusion criteria: history of chronic kidney diseases history of diabetes pregnant women or pregnancy during study history of secondary Immune thrombocytopenia (ITP) such as (Antiphospholipid syndrome, Myelodysplastic syndromes and vasculitis) patients under treatment with any drugs within 3-month before participating in study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet value in cell blood count test. Timepoint: Monthly. Method of measurement: Cell blood count test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect of treatment with corticosteroids. Timepoint: Six-months after treatment. Method of measurement: Clinical visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReyhaneh Azimi Noubari
Shahid Beheshti University of Medical Sciences
Outcome results
None listed